Open Access

Mixed-species Plasmodium falciparum and Plasmodium ovale malaria in a paediatric returned traveller

  • Heather Senn1,
  • Nadia Alattas2,
  • Andrea K Boggild3, 4, 5 and
  • Shaun K Morris2, 6Email author
Malaria Journal201413:78

https://doi.org/10.1186/1475-2875-13-78

Received: 23 December 2013

Accepted: 26 February 2014

Published: 5 March 2014

Abstract

Malaria is a common and potentially fatal cause of febrile illness in returned travellers. Endemic areas for different malaria parasites overlap, but mixed species infections are rare. An adolescent male returned from a trip to Ghana in late summer 2013. He subsequently presented with blood smears positive for two species of malaria parasite, Plasmodium falciparum and Plasmodium ovale, on two isolated hospital visits within a six-week period. The epidemiology of mixed infections, likely pathophysiology of his presentation, and the implications for malaria testing and treatment in returned travellers are discussed.

Keywords

Malaria Traveller Plasmodium falciparum Plasmodium ovale Mixed-species Paediatric Rapid diagnostic test

Background

Malaria remains the most commonly identified cause of fever in returned travellers, with the majority of infections acquired in sub-Saharan Africa [1]. Malaria can be caused by several different species of Plasmodium parasites with the largest burden of mortality and morbidity being due to Plasmodium falciparum. While Plasmodium species have different geographical distributions, there are areas of significant overlap. Thus, individuals may be infected with more than one species at any given time though this is rare in returned travellers [2]. Mixed infections, where more than one species are present either in the blood or liver stage of infection at one time, can have varied presentations. Different species have different clinical features and also require different treatments. Recently, a Canadian adolescent presented with symptoms of malaria twice within a six-week period to The Hospital for Sick Children (SickKids) in Toronto following a trip to West Africa. On both visits, he had multiple positive blood smears and each set was identified as a different Plasmodium species.

Case presentation

A previously healthy 16-year-old male went on a volunteer trip to Ghana for three weeks in June and July, 2013. He did not take malaria prophylaxis. He had been on a similar volunteer trip to Kenya one year previously during which he took appropriate malaria prophylaxis and received hepatitis A, typhoid and yellow fever vaccinations prior to departure. Ten days after his return from Ghana, he presented to a local emergency department with a four-day history of fever, chills, headaches, nausea, and vomiting. A blood smear was positive for malaria parasites, later identified as P. falciparum, with a parasitaemia of 2.5% by the Public Health Ontario Laboratory (PHOL). Plasmodium falciparum-specific histidine rich protein-2 (HRP-2) was detected by rapid diagnostic test (RDT), while Plasmodium genus aldolase was undetectable. The patient was transferred to SickKids with findings of hypotension, elevated liver enzymes (Alanine aminotransferase (ALT) 134 U./L; aspertate aminotransferase (AST) 106 U/L; Gamma glutamyl transferase (GGT) 55 U/L), and thrombocytopaenia (platelets 19 × 10^9/L). A subsequent pre-treatment blood smear was positive for P. falciparum with 2.4% parasitaemia. He was treated with a three-day course of intravenous artesunate and oral atovaquone/proguanil. On day 5 of his admission he had clinically improved, and was discharged home with normalizing blood work trends and a negative blood smear. P. falciparum HRP-2 remained detectable by RDT despite an absence of parasitemia by thick and thin film microscopy. He was subsequently seen in follow-up in the Infectious Diseases clinic at SickKids one week later and reported to be asymptomatic with a repeat blood smear confirming an absence of parasitaemia from PHOL.

However, the patient returned to the emergency room at SickKids one month later with a two-day history of recurring symptoms of headache, nausea and vomiting without a fever. A blood smear was performed which was positive for malaria parasites with a parasitaemia level of <0.1%. The remainder of his laboratory results were within normal limits. It was initially thought that he was experiencing a recrudescence of P. falciparum malaria. Repeat blood smears were drawn on three consecutive days and were sent to PHOL for species identification while he was treated with a three-day course of oral atovaquone/proguanil. His symptoms were comparatively mild and resolved quickly and he was discharged home within 48 hours. He was followed up in clinic after four days, at which time species identification was available. All three blood smears identified Plasmodium ovale with <0.1% parasitaemia. Again, P. falciparum HRP2 was detectable by RDT, while Plasmodium genus aldolase was undetectable. Due to the discrepancy between microscopy and RDT, Plasmodium genus-specific and species-specific quantitative real time PCR (qPCR) targeting 18S rRNA was performed as described [3]. qPCR confirmed isolated P. ovale infection. The patient was treated with four doses of chloroquine and, after ruling out G6PD deficiency, he subsequently began a 14-day course of primaquine. Clinic follow-up two weeks after completing treatment confirmed he was doing well and a repeat blood smear at that time was negative.

Discussion

Mixed species malaria infections are rare in travellers, comprising 2.1% of the 1,140 cases of malaria logged by the GeoSentinel Surveillance network based on treating physician diagnosis between 1997 and 2002 [2]. Mixed P. falciparum and P. ovale infections are especially uncommon, with only three instances (0.3%) reported in the above study. This statistic is in large part due to the rarity of P. ovale itself which accounted for only 5% of all malaria infections. A more recent study systematically tested over 1200 returned travellers from Italy who had at least 1 symptom of malaria with highly sensitive PCR testing. Of the 196 patients who tested positive for malaria, 3.1% had mixed-species infections including 2.0% testing positive for P. falciparum and P. ovale. Plasmodium ovale monoinfection accounted for 3.1% of malaria cases in this study [4]. In Ontario, over a six-year-period, 33 specimens from 29 patients with isolated P. ovale infection were identified by PHOL [3], underscoring the rarity of this infection in returned travellers. Mixed P. ovale and P. falciparum infections are also uncommon in areas where malaria is endemic. A study that followed 830 children in Burkina Faso from 2007–2010 found study participants had an overall malaria prevalence of 71% over the three years, and among those who presented with malaria, the rate of P. falciparum and P. ovale mixed infection was 0.72% [5]. Plasmodium ovale itself, again, was quite rare accounting for 1.08% of all recorded malaria infections.

While reported rates of P. ovale malaria are consistently low, there is evidence to suggest that infection with this species may actually be more common than most studies suggest. A research group in Senegal followed 101 children and 105 adults over a four-month malaria season with regular thick blood films regardless of the presence or absence of signs and symptoms of infection [6]. Although only three clinically significant P. ovale infections were documented, 48.5% of children and 32.5% of adults had blood films positive for P. ovale at some point during the study period suggesting that while infection with P. ovale may be common, the majority of infections are subclinical.

The two Plasmodium species have different life cycles and behaviours, accounting for the immediate and more severe presentation of P. falciparum malaria and delayed and milder course of P. ovale malaria in this patient. Plasmodium falciparum cycles through a transient liver phase, following which multiple schizonts rupture simultaneously and the infection proceeds to the symptomatic blood stage. This almost always occurs within two months of exposure. In contrast, P. ovale has a prominent liver hypnozoite phase. Parasites remain dormant in this stage and may persist for years. Presentation of P. ovale malaria is often delayed and hypnozoites rupture asynchronously producing intermittent symptoms of a milder nature. Specific treatment is required to target the hypnozoite phase to prevent relapse of infection. It is worth noting that the presentation of P. ovale and P. falciparum mixed infections cannot always be expected to follow this patient’s pattern. The timing of infection, variability of hypnozoite phase duration, interactions between species and other factors may play a role. A recent case report described a mixed-species infection where the patient presented first with P. ovale malaria with a subsequent delayed presentation of P. falciparum[7].

It is likely that the patient contracted both Plasmodium species during his recent trip to Ghana, with the presentation of P. ovale being either initially masked by the higher parasitaemia of P. falciparum or delayed while it remained in the hypnozoite phase. The possibility that this patient acquired his P. ovale infection during his trip to Kenya the year prior cannot be excluded. Although entomological data exists for co-infected mosquitoes, rates of confirmed mosquito co-infection are very low and most cases of mixed malaria infection are thought to be acquired from two separate inoculations [8]. Rapid diagnostic testing (RDT) is routinely performed as part of malaria screening to compliment blood smear identification in haematology and public health laboratories in Canada [9]. Although approved RDTs can detect P. falciparum and Plasmodium vivax, specific testing for P. ovale is not available. Current assays developed to detect mixed malaria infections have suboptimal sensitivity for the diagnosis of P. ovale[10, 11]. An added disadvantage of RDTs is their prolonged detection of circulating antigen for weeks following effective malaria treatment [12], which can confuse the clinical picture. Persistent antigenemia, as seen in this case, can lead to an over-diagnosis of treatment failure, or misattribution of new symptoms to a relapsed or recrudesced prior infection.

The more sensitive malaria PCR, a costly test which is not routinely performed, is helpful in arbitrating incongruent results of microscopy and RDT, in identifying very low parasitemia infections, and in identifying those parasites with aberrant morphology on microscopy [4, 13, 14]. As described above, this test is available at PHOL, which uses one genus-specific and two duplex, species-specific real time quantitative PCR (qPCR) assays targeting the 18S rRNA region for the identification of Plasmodium species as described [3].

While appropriate prophylaxis would likely have prevented P. falciparum infection, it may not have prevented P. ovale infection. There have been case reports of returned travellers receiving appropriate prophylaxis who nevertheless present with P. ovale malaria [15, 16]. This has also been reported for P. vivax, another Plasmodium species with a hypnozoite phase [17, 18]. How frequently this occurs is unknown. Typical drugs used for prophylaxis such as atovaquone/proguanil do not successfully treat the liver phase of malaria infection, and any remaining liver schizonts can progress to the blood phase of infection once prophylaxis has stopped. The Centers for Disease Control thus recommend primaquine prophylaxis in areas of high P. vivax prevalence as well as a terminal prophylaxis in long-term travellers to endemic areas of relapsing malaria [19]. Relapses can occur up to several years after the initial infection for P. ovale, raising the possibility that while not likely, the patient described in this report may have contracted P. ovale during his previous trip to Kenya even though he took appropriate prophylaxis [2023]. His recent symptoms could have been his first presentation, or he may have had previous reactivations that were not recognized as malaria. This highlights the importance of considering malaria in the differential diagnosis of symptomatic patients for months to years after travel to endemic areas, particularly if they present with a history of intermittent, recurrent illness.

In contrast to P. falciparum, P. ovale is almost universally chloroquine sensitive. Very few studies have attempted to determine the sensitivity of the blood stage of P. ovale to alternative therapies such as atovaquone/proguanil. One small study from 1996 treated seven adults presenting with Plasmodium malariae or P. ovale malaria with atovaquone and proguanil [24]. Each of the patients was cured of their infection. Another case report documented a single adult patient who cleared a P. ovale infection with atovaquone/proguanil [25]. The Centers for Disease Control guidelines for malaria treatment state that treatment regimens effective for P. falciparum are also acceptable for P. ovale[19]. Nevertheless, given the sparse data available, and because the patient’s most recent blood smear, taken on the last day of atovaquone/proguanil treatment, remained positive, the confirmed P. ovale infection was treated with chloroquine for 48 hours to clear the blood phase, followed by a two-week course of primaquine to clear the hypnozoite phase.

Conclusion

In the summer of 2013, a paediatric returned traveller presented to SickKids with a rare, mixed-species malaria infection. He initially presented with more severe P. falciparum malaria, then returned one month later with milder symptoms and a blood smear positive for P. ovale. Mixed malaria infections are rare in returned travellers, and P. ovale itself is a rare cause of documented malaria that often has mild symptoms, delayed presentation, and may cause subclinical infections in the majority of cases. Compared to other species of malaria, little is known about this parasite’s actual prevalence and response to different anti-malarial therapies. This case highlights the value of accurate speciation of malaria blood films, and follow-up to ensure patients receive appropriate treatment including radical cure, if indicated, of the identified parasite. It also raises the possibility that more sensitive testing, such as PCR, may be useful in the setting of recurrent illness. It demonstrates the importance of considering malaria in the differential diagnosis of returned travellers with delayed symptoms, regardless of their use of prophylactic medications or previous malaria treatment. More generally, this case reinforces the importance of pre-travel physician counselling and adequate malaria prophylaxis for trips to endemic areas.

Consent

Written informed consent was obtained from the patient for publication of this Case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Acknowledgements

The authors would like to thank the staff of the Division of Paediatric Infectious Diseases and Medical Microbiology at SickKids for their helpful discussions around this case, and PHOL for critical appraisal of the manuscript. Special thanks to the Division of Pediatric Medicine at SickKids who looked after the patient during his admission, and to the technologists at the SickKids microbiology lab and PHOL who performed the diagnostic tests cited.

Authors’ Affiliations

(1)
University of Toronto Faculty of Medicine, 1 King’s College Circle
(2)
Division of Infectious Diseases, Hospital for Sick Children
(3)
Tropical Disease Unit, Division of Infectious Diseases, University Health Network-Toronto General Hospital
(4)
Department of Medicine, University of Toronto
(5)
Public Health Ontario Laboratories
(6)
Department of Paediatrics, The Hospital for Sick Children

References

  1. Leder K, Torresi J, Libman MD, Cramer JP, Castelli F, Schlagenhauf P, Wilder-Smith A, Wilson ME, Keystone JS, Schwartz E, Barnett ED, Von Sonnenburg F, Brownstein JS, Cheng AC, Sotir MJ, Esposito DH, Freedman DO: GeoSentinel surveillance of illness in returned travelers, 2007–2011. Annals Int Med. 2013, 158: 456-468. 10.7326/0003-4819-158-6-201303190-00005.View ArticleGoogle Scholar
  2. Leder K, Black J, Greenwood Z, Kain K, Schwartz E, Brown G, Torresi J: Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis. 2004, 39: 1104-1112. 10.1086/424510.View ArticlePubMedGoogle Scholar
  3. Phuong M, Lau R, Ralevski F, Boggild AK: Sequence-based optimization of a quantitative real-time PCR assay for the detection of Plasmodium ovale and P. malariae. J Clin Microbiol. 2014, [Epub ahead of print]Google Scholar
  4. Paglia MG, Vairo F, Bevilacqua N, Ghirga P, Narciso P, Severini C, Nicastri E: Molecular diagnosis and species identification of imported malaria in returning travellers in Italy. Diagn Microbiol Infect Dis. 2012, 72: 175-180. 10.1016/j.diagmicrobio.2011.09.013.View ArticlePubMedGoogle Scholar
  5. Gneme A, Guelbeogo W, Riehle M, Tiono A, Diarra A, Kabre G, Sagnon N, Vernick K: Plasmodium species occurrence, temporal distribution and interaction in a child-aged population in rural Burkina Faso. Malar J. 2013, 12: 67-10.1186/1475-2875-12-67.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Faye FB, Konate L, Rogier C, Trape JF: Plasmodium ovale in a highly malaria endemic area of Senegal. Trans R Soc Trop Med Hyg. 1998, 92: 522-525. 10.1016/S0035-9203(98)90900-2.View ArticlePubMedGoogle Scholar
  7. Menner N, Borchert M, Dieckmann S, Ignatius R, Mockenhaupt FP: Uncommon manifestation of a mixed-species malaria infection: cryptic falciparum malaria in a traveler with successfully treated tertian malaria. J Travel Med. 2012, 19: 133-135. 10.1111/j.1708-8305.2011.00595.x.View ArticlePubMedGoogle Scholar
  8. Imwong M, Nakeesathit S, Day NPJ, White NJ: A review of mixed malaria species infections in anopheline mosquitoes. Malar J. 2011, 10: 253-10.1186/1475-2875-10-253.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Public Health Agency of Canada: Canadian recommendations for the prevention and treatment of malaria among international travellers. [http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s1/], accessed on November 26, 2013
  10. Bigaillon C, Fontan E, Cavallo JD, Hernandez E, Speigel A: Ineffectiveness of the Binax NOW malaria test for diagnosis of Plasmodium ovale malaria. J Clin Microbiol. 2005, 43: 1011-10.1128/JCM.43.2.1011.2005.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Farcas GA, Zhong KJ, Lovegrove FE, Graham CM, Kain KC: Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am J Trop Med Hyg. 2003, 69: 589-592.PubMedGoogle Scholar
  12. Kyabayinze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H: Operational accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for Plasmodium falciparum malaria in a hyperendemic region of Uganda. Malar J. 2008, 7: 221-10.1186/1475-2875-7-221.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR: Multiplex real-time quantitative PCR, microscopy and rapid diagnostic immune-chromatographic tests for the detection of Plasmodium spp: performance, limit of detection analysis and quality assurance. Malar J. 2009, 8: 284-10.1186/1475-2875-8-284.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Zakeri S, Najafabadi ST, Zare A, Djadid ND: Detection of malaria parasites by nested PCR in south-eastern, Iran: evidence of highly mixed infections in Chahbahar district. Malar J. 2002, 1: 2-10.1186/1475-2875-1-2.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Gallien S, Taieb F, Schlemmer F, Lagrange-Xelot M, Atlan A, Sarfati C, Molina JM: Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. Travel Med Infect Dis. 2008, 6: 128-129. 10.1016/j.tmaid.2008.01.011.View ArticlePubMedGoogle Scholar
  16. Jimenez BC, Navarro M, Huerga H, Lopez-Roman E, Mendoza A, Lopez-Velez R: Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. J Travel Med. 2006, 13: 373-375. 10.1111/j.1708-8305.2006.00073.x.View ArticlePubMedGoogle Scholar
  17. Mavrogordato A, Lever AM: A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax. J Infect. 2012, 65: 269-274. 10.1016/j.jinf.2012.04.015.View ArticlePubMedGoogle Scholar
  18. Povinelli L, Monson TA, Fox BC, Parise ME, Morrisey JM, Vaidya AB: Plasmodium vivax malaria in spite of atovaquone/proguanil (Malarone) prophylaxis. J Travel Med. 2003, 2003 (10): 353-355.Google Scholar
  19. Centers for Disease Control and Prevention: Treatment of malaria (guidelines for clinicians). [http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf], accessed on November 26, 2013
  20. Davis TM, Singh B, Sheridan G: Parasitic procrastination: late-presenting ovale malaria and schistosomiasis. Med J Aust. 2001, 175: 146-148.PubMedGoogle Scholar
  21. Centers for Disease Control and Prevention: Late relapse of Plasmodium ovale malaria—Philadelphia, Pennsylvania, November 2004. MMWR Morb Mortal Wkly Rep. 2005, 54: 1231-1233.Google Scholar
  22. Han TH, Kim B, Seong HK: A case of imported Plasmodium ovale malaria. J Korean Med Sci. 2006, 21: 932-935. 10.3346/jkms.2006.21.5.932.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Kang Y, Yang J: A case of Plasmodium ovale malaria imported from West Africa. Korean J Parasitol. 2013, 51: 213-218. 10.3347/kjp.2013.51.2.213.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Radloff PD, Philipps J, Hutchinson D, Kreusner PG: Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Trans R Soc Trop Med Hyg. 1996, 90: 682-10.1016/S0035-9203(96)90435-6.View ArticlePubMedGoogle Scholar
  25. Kimura M, Koga M, Kikuchi T, Miura T, Maruyama H: Efficacy and safety of atovaquone-proguanil in treating imported malaria in Japan: the second report from the research group. Parasitol Int. 2012, 61: 466-469. 10.1016/j.parint.2012.03.004.View ArticlePubMedGoogle Scholar

Copyright

© Senn et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.